Global Blood Therapeutics Inc. (GBT) is a biopharmaceutical company that develops and commercializes therapies for patients with blood disorders. The company's lead product, Oxbryta (voxelotor), is an oral therapy approved by the FDA for the treatment of sickle cell disease (SCD) in patients aged 12 years and older.
GBT's research and development efforts are focused on developing therapies that target the underlying genetic and molecular mechanisms of blood disorders, with the goal of improving patient outcomes and quality of life. The company has a robust pipeline of potential therapies for SCD and other blood disorders, including:
GBT601: A selective, once-daily oral prophylactic therapy for SCD that targets the underlying cause of vaso-occlusive crises, a painful complication of the disease.
GBT711: An oral, once-daily therapy for the treatment of polycythemia vera, a rare blood disorder characterized by the overproduction of red blood cells.
Other preclinical programs targeting other blood disorders, including hereditary angioedema and paroxysmal nocturnal hemoglobinuria.
GBT has a strong commitment to patient advocacy and works closely with patient communities to ensure that its therapies meet the needs of patients with blood disorders. The company also has a focus on diversity and inclusion, and aims to create a culture that reflects the diversity of the patients it serves. As of February 18, 2023, GBT was listed on the NASDAQ stock exchange under the symbol GBT, with a market capitalization of approximately $3.2 billion.
|
